Bolt Biotherapeutics Aktie

Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,971 shares of the company’s stock, valued at approximately $26,000. Squarepoint Ops LLC owned about 0.13% of Bolt Biotherapeutics as of its most recent SEC filing. Separately, Millennium Management LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $25,000. Institutional investors own 86.70% of the company’s stock. Bolt Biotherapeutics Stock Performance Shares of BOLT opened at $6.64 on Wednesday. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $254.58 million, a PE ratio of -3.88 and a beta of 0.91. The company’s 50 day simple moving average is $6.76 and its 200-day simple moving average is $8.90. Bolt Biotherapeutics, Inc. has a 12-month low of $5.20 and a 12-month high of $15.60. Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.80) by $1.00. The business had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, equities analysts predict that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year. Wall Street Analysts Forecast Growth Several equities analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a “hold” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday, March 25th. Finally, Lake Street Capital initiated coverage on shares of Bolt Biotherapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $80.00 target price on the stock. Check Out Our Latest Stock Analysis on BOLT Bolt Biotherapeutics Profile (Free Report) Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.» Mehr auf defenseworld.net

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.28 per share a year ago.» Mehr auf zacks.com

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapies,” said Willie Quinn, Chief Executive Officer. “We recently presented promising early clinical data for BDC-3042 at AACR and launched a process to find a partner to accelerate BDC-3042 development. We also just opened enrollment for the first next-generation Boltbody™ ISAC in our pipeline, BDC-4182. We are excited to see what our ISAC platform technology can do for gastric and gastroesophageal cancer patients. We continue to be good stewards of capital as we execute against our mission to deliver new treatment options to patients with cancer.”» Mehr auf globenewswire.com